AxCell Wins US Patent Covering Synthetic Ligand-Based Proteomic Technology | GenomeWeb

NEW YORK, Nov. 1 - AxCell Biosciences has been awarded a US patent covering nine claims to the company's Cloning of Ligand Targets proteomics technology, AxCell said on Thursday.

“This technology permits the use of ligands … to discover new domains and ultimately new proteins that may be useful as drug targets,” John Rodwell, president and chief technical officer of AxCell, said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.